Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Inflammatory Cells Suppliers In Europe
4 companies found
based inCarasco, ITALY
mectron has been active and successful in the dental field since 1979, developing and producing top-quality devices. The company has always stood out on the market for its continuous process of development and innovation and the excellent design of ...
PIEZOSURGERY® flex is an efficient, versatile and user-friendly device offering safety and precision in all situations. ...
based inGlasgow, UNITED KINGDOM
Our mission is to enhance decision making within R&D by leveraging Digital Pathology to deliver robust data and actionable insights. OracleBio is a global leader in quantitative digital pathology, providing image analysis services to Pharma and ...
At OracleBio, we have extensive experience in providing pre-clinical services to support clients in the early stages of the drug discovery pipeline. We understand that our clients need their data quickly, so we work hard to ensure a fast ...
based inTienen, BELGIUM
As the pioneer of hemodialysis machines in Japan, the Nikkiso Medical Division continues to improve dialysis medical care and patient QOL. Part of the Nikkiso Group, our Medical division can look back on a company history of more than half a ...
Immunopure is a novel medical device that offers a therapeutic option in the treatment of patient suffering from Ulcerative ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
During the development of the anti-glycan monoclonal antibodies (mAbs), Scancell identified unique sequence residues in the Fc region that enable mAbs to self-associate upon target recognition, resulting in more potent, high avidity ...